Joyce O'Shaughnessy

6PUBLICATIONS
0CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|May 11, 2022
Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.

Joyce O'Shaughnessy, Adam Brufsky, Hope S Rugo

|May 22, 2020
Treatment options for patients with HR+/HER2- advanced breast cancer during the COVID-19 pandemic: dose reduction of ribociclib does not diminish efficacy.

Joyce O'Shaughnessy

|Apr 21, 2018
A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation.

Joyce O'Shaughnessy, Angela DeMichele, Cynthia X Ma

|Nov 23, 2017
Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial.

Joyce O'Shaughnessy, Katarina Petrakova, Gabe S Sonke

|Sep 09, 2017
Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.

Javier Cortés, Hope S Rugo, Ahmad Awada

|Jun 15, 2017
Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.

Javier Cortés, Hope S Rugo, Ahmad Awada

Pageof 1

Frequent Collaborators